Two studies examining the use of glucagon-like peptide-1 receptor agonists, including semaglutide, have found short- and long-term associations in orthopedic postoperative outcomes and general ...

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...

Spending on GLP-1s in Medicaid has followed broader industry trends, growing significantly over the past several years, according to a new study from KFF. The analysis found that the number of ...

USDA data shows snack sales holding steady in 2024, even as GLP-1 weight loss drug use rises, highlighting shifting consumer ...

Medicaid spending on GLP-1 drugs has skyrocketed in recent years as demand for the medications has steadily climbed — even though coverage remains limited, according to a recent report from the Kaiser ...

The risk for nonscarring hair loss (NSHL) is increased in association with glucagon-like peptide-1 receptor agonist (GLP-1 RA) use.

Obesity dipped in Minnesota as GLP‑1 use rose. Experts warn the long‑term picture and who pays are still unsettled.